2023-03-29
The city of Guangzhou welcomes Singapore Prime Minister Lee Hsien Loong, the first stop of his week-...
News
BioSyngen is developing multiple T-cell immunotherapies with the aim to address a wide range of malignancies.
2023-03-29
The city of Guangzhou welcomes Singapore Prime Minister Lee Hsien Loong, the first stop of his week-...
2022-11-16
Biosyngen featured in the “Top 50 Most Innovative Companies of Chinese Biomedicine in 2022”, Pharma BigstarOn November 10th to 11th, 2022, the Shanghai (Minhang) Biopharmaceutical Industry Innovation
2022-10-20
Prof. Jean Paul Thiery, Biosyngen’s Chief Scientist, is ranked among the World’s Top 2% Clinical Scientists 2022Professor Jean Paul Thiery, Biosyngen’s Chief Scientist and Chairman of Scientific Advis
2022-10-21
SINGAPORE, Sept. 28, 2022 /PRNewswire/ — On September 22nd, Biosyngen signed to set up a Cell Therapy GMP Facility which will serve as a bas
2022-09-22
SINGAPORE, Sept. 28, 2022 /PRNewswire/ — On September 22nd, Biosyngen signed to set up a Cell Therapy GMP Facility which will serve as a bas
2022-05-28
SINGAPORE, Sept. 28, 2022 /PRNewswire/ — On September 22nd, Biosyngen signed to set up a Cell Therapy GMP Facility which will serve as a bas
2022-01-15
SINGAPORE, Sept. 28, 2022 /PRNewswire/ — On September 22nd, Biosyngen signed to set up a Cell Therapy GMP Facility which will serve as a bas
2021-12-29
SINGAPORE, Sept. 28, 2022 /PRNewswire/ — On September 22nd, Biosyngen signed to set up a Cell Therapy GMP Facility which will serve as a bas
2021-10-20
Singapore-based biotech firm Biosyngen has set its sights on developing these cell therapies to benefit an even larger group of cancer patients. PHOTO: BIOSYNGEN
2021-10-21
SINGAPORE, Sept. 28, 2022 /PRNewswire/ — On September 22nd, Biosyngen signed to set up a Cell Therapy GMP Facility which will serve as a bas
Copyright © 2023
Biosyngen Pte. Ltd.
Copyright © 2022 Biosyngen Pte. Ltd.
MENU